Tag: aduro biotech
September 4, 2019
Aduro Biotech Doses First Patient in Phase 2 Study of ADU-S100
Aduro Biotech (NASDAQ:ADRO) has announced it has dosed the first patient in its Phase 2 clinical trial of ADU-S100 as... February 11, 2019
Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100
Aduro Biotech (NASAQ:ADRO) has announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 for... December 19, 2018
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
Eli Lilly (NYSE:LLY) and Aduro Biotech (NASDAQ:ADRO) today announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway...
December 17, 2018
Biotech Trends 2018: Immuno-oncology Disappoints
2018 marked another critical year of growth for the biotech market. Learn about key biotech trends before the new year... June 8, 2018